Prognostic role of long non-coding RNA LINC00152 in Chinese cancer patients: a meta-analysis
Metrics: PDF 378 views | HTML 1146 views | ?
Liyang Liu1,*, Jianfei Wen2,*, Xi Gu1,*, Dongdong Wu1, Ming Lu1 and Qinghong Zhao1
1Department of General Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
2Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
*These authors contributed equally to this work and Co-first authors
Qinghong Zhao, email: firstname.lastname@example.org
Keywords: LINC00152, cancer, metastasis, prognosis, meta-analysis
Received: July 20, 2017 Accepted: September 21, 2017 Published: October 12, 2017
The role of long intergenic non-coding RNA 152 (LINC00152) in predicting the prognosis of cancer has been investigated but results remain inconclusive and inconsistent. A meta-analysis was performed to explore the effect of LINC00152 on cancer prognosis. PubMed and ScienceDirect were searched for suitable studies and the results of 10 studies with a total of 775 patients were pooled. Pooled hazard ratios (HRs) and odds ratios (ORs) were calculated to assess the prognostic value of LINC00152. The results revealed that tumour patients with high LINC00152 expression were more likely to have lymph node metastasis (OR = 2.94, 95% CI 1.97–4.40, P < 0.001) and unfavourable tumour–node–metastasis stage (grade III/IV vs. I/II: OR = 3.07, 95% CI 1.69–5.59, P < 0.001). In addition, high LINC00152 expression levels were significantly associated with poor overall survival (pooled HR = 1.99, 95% CI 1.54–2.56, P < 0.001). The results suggest that high LINC00152 expression may serve as a predictive biomarker for the poor prognosis of various cancers in the Chinese population.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.